Table 2.
Use of classes of glucose lowering medications by patient characteristics
| n | Metformin | SU | Insulin | DPP-4i | TZD | GLP-1 RA | SGLT2i | |
|---|---|---|---|---|---|---|---|---|
| Age | ||||||||
| <65 years | 55,618 | 81.0% | 27.9% | 28.8% | 18.2% | 9.2% | 9.4% | 8.3% |
| 65 to <75 years | 54,092 | 77.1% | 34.7% | 28.2% | 18.4% | 11.6% | 6.7% | 4.0% |
| ≥75 years | 47,841 | 66.1% | 41.6% | 25.8% | 18.2% | 12.0% | 2.7% | 1.6% |
| p-value | <0.001 | <0.001 | <0.001 | 0.924 | <0.001 | <0.001 | <0.001 | |
| Body mass index | ||||||||
| <30 kg/m2 | 43,738 | 73.6% | 34.9% | 23.7% | 19.4% | 9.4% | 3.5% | 3.8% |
| 30 to <40 kg/m2 | 50,182 | 75.4% | 34.5% | 30.1% | 19.2% | 10.6% | 7.8% | 5.4% |
| ≥40 kg/m2 | 15,040 | 73.2% | 32.3% | 37.3% | 17.0% | 11.6% | 11.2% | 5.6% |
| p-value | 0.095 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| Estimated GFR | ||||||||
| <30 mL/min per 1.73 m2 | 3,585 | 26.8% | 43.4% | 62.5% | 20.0% | 12.5% | 5.2% | 0.7% |
| 30 to <60 mL/min per 1.73 m2 | 27,779 | 61.8% | 42.8% | 36.5% | 21.8% | 13.1% | 6.6% | 3.2% |
| ≥60 mL/min per 1.73 m2 | 48,000 | 82.3% | 31.1% | 24.5% | 18.3% | 10.3% | 6.8% | 5.7% |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.008 | <0.001 | |
| Coronary artery disease | ||||||||
| Yes | 88,475 | 37.7% | 71.6% | 32.2% | 18.6% | 11.4% | 5.9% | 4.0% |
| No | 69,076 | 30.1% | 79.6% | 21.9% | 17.9% | 10.3% | 7.2% | 5.8% |
| p-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
SU, sulfonylurea; TZD, Thiazolidinedione; DPP-4i, Dipeptidyl Peptidase-4 inhibitors; GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonists; SGLT2i, Sodium-glucose co-transporter 2 inhibitors; GFR, glomerular filtration rate
p-values correspond to the unadjusted comparisons across groups using chi-square tests